XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenue $ 582 $ 68
Cost of revenues 96 236
Gross profit (loss) 486 (168)
Operating expenses:    
Research and development 4,604 5,920
General and administrative 13,132 14,587
Gain on lease termination (1,576)
Acquisition of Exacis in-process research and development 460
Total operating expenses 16,160 20,967
Loss from operations (15,674) (21,135)
Other (expense) income, net:    
Loss on extinguishment of debt (22,440)
Change in fair value of convertible notes 1,017
Change in fair value of bridge notes derivative liability (1,459)
Change in fair value of warrant liabilities 414 215
Change in fair value of contingent consideration 66 118
Loss on non-controlling investment (59)
Interest income 249 138
Interest expense (6,752) (614)
Other income (expense), net 70 (334)
Total other expense, net (28,835) (536)
Loss before income taxes (44,509) (21,671)
(Provision) benefit for income taxes (30) 3
Net loss (44,539) (21,668)
Series A preferred stock dividend (16) (16)
Net loss attributable to common stockholders $ (44,555) $ (21,684)
Net loss per common share - basic $ (3.26) $ (4.08)
Net loss per common share - diluted $ (3.26) $ (4.08)
Weighted average shares outstanding - basic 13,647 5,314
Weighted average shares outstanding - diluted 13,647 5,314